I don't think OPTR has much a choice. It had been on auction block for quite some time now. I suppose this is the best deal they could get. If OPTR shareholders bark, I think CBST would walk away because they have a competing drug for CDIFF in ph3.
I am just getting around to listening to the call not that I follow any of the companies closely but I noticed the Optimer CVR is publicly traded but the Trius one is not. There must be some rational behind that but I don't know. Does anyone have any insight as to why this would be structured in this fashion?
Market Data 
Markets 
AI
